RESEARCH

The telomerase gene polymorphisms, but not telomere length, increase susceptibility to primary glomerulonephritis/end stage renal diseases in females

Qing Sun1†, Junli Liu2†, Guanghui Cheng1, Mingkai Dai1, Jiaxi Liu1, Zhenqiang Qi3, Jingjie Zhao2, Wei Li3*, Feng Kong1*, Gang Liu4*, Magnus Björkholm5 and Dawei Xu5*

Abstract

Background: Primary glomerulonephritis (GN) is the leading cause of chronic kidney disease (CKD) and frequently progresses into end stage renal diseases (ESRDs). Shorter leukocyte telomere length (LTL) has been implicated in the CKD susceptibility and diminished kidney function, however, it is unclear whether the variants in telomerase genes contribute to risk to GN/CKD/ESRD. Here we address this issue by determining their association with the genetic variants of rs12696304 at the telomerase RNA component (TERC) and rs2736100 at the telomerase reverse transcriptase (TERT) loci.

Methods: The study includes 769 patients (243 primary GN-derived CKD and 526 ESRD cases) and sex-/age-matched healthy controls. Genomic DNA was extracted from peripheral blood of both controls and patients. Genotyping of rs12696304 and rs2736100 variants was carried out using PCR-based assays. Leukocyte telomere length (LTL) was determined using quantitative PCR (qPCR).

Results: A significantly higher frequency of TERC rs12696304 G allele was observed in patients and associated with increased disease risk (C vs G: OR = 1.334, 95% CI 1.112–1.586, P = 0.001; CC + GC vs GG: OR = 1.334, 95% CI 1.122–1.586, P = 0.001). Further analyses showed that such significant differences were only present between female controls and patients (C vs G: OR = 1.483, 95% CI 1.140–1.929, P = 0.003; CC + GC vs CC: OR = 1.692, 95% CI 1.202–2.383, P = 0.003), but not males. There were no differences in rs2736100 variants between controls and patients, but female ESRD patients carried significantly higher C allele frequencies than did female controls (A vs C: OR = 1.306, 95% CI

*Correspondence: lweidw@163.com; kongfeng@sdu.edu.cn; lg-2000@163.com; Dawei.Xu@ki.se
†Qing Sun and Junli Liu contributed equally to this work
1 Central Research Laboratory, Shandong University Second Hospital, Jinan 250035, People’s Republic of China
2 Department of Nephrology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250013, People’s Republic of China
3 Department of Nephrology, Affiliated Hospital of Shandong University, Jinan 250035, People’s Republic of China
4 Nephrology Research Institute of Shandong University, Shandong University Second Hospital, Jinan 250035, People’s Republic of China
5 Department of Medicine, Center for Molecular Medicine and Bioclinicum, Karolinska Institutet, Karolinska University Hospital Solna, SE-171 76 Stockholm, Sweden
Full list of author information is available at the end of the article

© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

The prevalence of chronic kidney disease (CKD) has significantly increased in the last decades, affecting more than 10% of the adult population worldwide [1]. In general, primary glomerulonephritis (GN) is a leading cause of CKD and frequently progresses into end-stage renal disease (ESRD) [1, 2], which has been a great burden to the public health care system [3]. The precise pathogenesis of primary GN/CKD is unclear, but the host-genetic background is implicated in the disease onset and progression [4–6]. Epidemiological studies showed striking geographic and ethnical variations [2, 4]. Consistently, recent genome-wide association studies (GWAS) and genetic analyses revealed a panel of genetic variants associated with the disease susceptibility and/or complications [4–9].

Human linear chromosomes terminate with telomeric TTAGGG repeat sequences essential for genomic stability and integrity [10–12]. Telomeric DNA is synthesized by telomerase, an RNA-dependent DNA polymerase with telomerase reverse transcriptase (TERT) and telomerase RNA template (TERC) as its core components [11–13]. Most human somatic cells express no or low levels of telomerase activity, which, together with “the end-replication problem”, results in progressive telomere shortening with cellular divisions [10–12]. When telomere becomes too short (dysfunctional) to protect chromosomes, the DNA damage response is activated, thereby triggering the permanent growth arrest of cells so-called replicative senescence. Thus, telomere erosion serves as a mitotic clock recording the number of cell divisions and limiting their life-span, and is widely accepted as a biomarker for aging and age-related conditions [10–12, 14]. Indeed, short leukocyte telomere length (LTL) has been shown to be associated with cancer, increased mortality, cardiovascular disorders, stroke, diabetes, and other age-related disorders [10, 15]. Similarly, shorter LTL-carriers were reported to display significantly decreased glomerular filtration rate while increased urinary albumin-creatinine ratio [16–18]. Carrero et al. and others further observed that CKD or ESRD patients had accelerated telomere attrition coupled with increased mortality [19, 20]. These findings suggest that shorter LTL is likely associated with CKD prevalence/occurrence or declining kidney function. However, there are published reports showing the lack of such an association [17]. In addition, because adverse environmental factors are capable of driving premature telomere erosion, the causal relationship between shortened LTL and GN/CKD/ESRD remains unclear.

There exist multiple single nucleotide polymorphisms (SNPs) in the telomerase genes and some of them are significantly associated with LTL in the general population, and risk of disorders as described above [21–29]. However, the relationship between these SNPs and GN/CKD/ESRD risk has not been explored yet so far. Moreover, unlike LTL, these germline variants are not affected by environmental elements. In the present study, we thus sought to determine whether rs12696304 at the TERC and rs2736100 at the TERT loci, two well characterized LTL-related SNPs, contribute to susceptibility to primary GN/CKD/ESRD.

Methods

Study populations

The case–control individuals include 515 healthy controls and 769 primary GN/CKD/ESRD patients and they were all Han Chinese. Primary non-end stage GN/CDK patients (n=243) were recruited from the out-patient service/department or ward, at Shandong University Second Hospital, Shandong University Qilu Hospital, Shandong Provincial Hospital and the Affiliated Hospital of Shandong University of Traditional Chinese Medicine, between June 2016 and Jan. 2018. ESRD patients, developed from primary GN, were included from Shandong University Second Hospital, between Jan. 2012 and Dec. 2017 and blood was collected before they underwent kidney transplantation. Five hundred and fifteen unrelated healthy controls who were age- and sex-matched to cases were recruited from the Physical Examination Center of Shandong University Second Hospital. All of the included controls had normal kidney function. The study was approved by the Ethics Review Committee of Shandong University Second Hospital and informed consent was obtained from all participants.

DNA extraction and genotyping of the TERC rs12696304 and TERT rs2736100 variants

Genomic DNA was extracted from peripheral blood cells using TIANGEN DNA extraction kits. The TERC rs12696304(C/G) and TERT rs2736100 (A/C) genotyping
was carried out using pre-designed TaqMan SNP genotyping assay kits on an ABI 7500 Life Tech (Applied Biosystems), as described [30]. Both positive and negative controls were included in all assays and the running condition was as followed: 95 °C for 5 min, followed by 40 cycles of 92 °C for 15 s and 60 °C for 30 s.

**LTL assay**
Genomic DNA was isolated from peripheral blood cells as described above and LTL was assessed using real-time PCR as previously described [31, 32]. Briefly, 2 ng of DNA were used for each PCR reaction. The primer sequences for human telomere (Tel 1b and Tel 2b) and β-globin (HBG3 and HBG4) were: Tel1b: 5′-CGGTTT TGG GTT TGG GT-TTG GGT TTG GGT TTG GGT T-3′; Tel2b: 5′-GCGTTGCTTACCCCTACCCCTAC CC-TTACCCCTACCCT-3′; HBG3: 5′-TGCTGGGCG CCATCACTTTG-3′, and HBG4: 5′-ACCAGCCA-CCA CTTCTGATAGG-3′. T/HBG values were determined using the formula T/S = 2−ΔCt, where ΔCt = average Ctβ-globin − average Ct telomere. The T/S ratio was arbitrarily expressed as LTL. Age-adjusted LTL for each control and patient was done by subtracting the subject’s linear predicted LTL from the observed one.

**Statistical analyses**
The evaluation of distribution differences of selected variables and alleles of the TERC rs12696304 and TERT rs2736100 between GN/CKD/ESRD patients and healthy controls were done using χ2 test. Hardy–Weinberg equilibrium of the genotype distribution among the controls and cases were tested by a goodness-of-fit χ2 test. Unconditional univariate and multivariate logistic regression analyses were used to estimate Odd ratios (ORs) for risk of GN/CKD/ESRD and their 95% confidence intervals (CIs). The LTL difference between patients and healthy controls was assessed using Student T test. All the tests were computed using SPSS17.0 software. For comparison of rs12696304 and rs2736100 alleles and genotypes between healthy controls and GN/CKD/ESRD patients, P values of <0.05 were considered as statistically significant.

**Results**

**Characteristics of study subjects**
A total of 769 patients with primary GN/CKD/ESRD were included in the present study. Age and sex distributions are shown in Table 1. Five hundred and fifteen unrelated healthy adults used as controls were age- and sex-matched (Table 1). Both controls and patients were genotyped for TERC rs12696304 and TERT rs2736100 variants. LTL was assessed in 327 controls and 592 patients.

**Table 1 Characteristics of primary GN/CKD/ESRD patients & healthy controls**

|                         | Primary GN | ESRDs | Healthy controls |
|-------------------------|------------|-------|------------------|
| Number                  | 243        | 526   | 515              |
| Age (year)              |            |       |                  |
| Range                   | 13–81      | 15–83 | 15–86            |
| Mean ± SD               | 43 ± 14    | 46 ± 11 | 46 ± 12         |
| Gender                  |            |       |                  |
| Male                    | 133        | 301   | 289              |
| Female                  | 110        | 225   | 226              |

**The association between the rs12696304 G allele or GG genotype and susceptibility to primary GN/CKD/ESRD**
We first determined rs12696304 and rs2736100 allele/genotype distribution in both controls and patients with GN/CKD/ESRD. Genotyping was successfully performed on DNA from all 515 controls and 757/769 patients for rs2736100, and all 515 controls and 759/769 patients for rs12696304, respectively. The results, summarized in Table 2, showed a significantly increased frequency of rs12696304 G allele in the patient group compared to that in controls (C vs G: OR = 1.465, 95% CI 1.170–1.834, P = 0.001; Table 2). Similarly, a higher frequency of the rs12696304 GG genotype was observed in the patient group (CC vs GG: OR = 1.334, 95% CI 1.122–1.586, P = 0.001; Table 2). Because our previous studies showed that telomerase gene variant-associated disease susceptibility was gender-dependent [32, 33], we compared males and females separately. The significant difference was only confined to female controls and patients (C vs G: OR = 1.483, 95% CI 1.140–1.929, P = 0.003; CC + GC vs CC: OR = 1.692, 95% CI 1.202–2.383, P = 0.003; Table 2), whereas not seen in the male groups (Table 2). These findings thus suggest that the rs12696304 G allele and GG genotype are significantly associated with primary GN/CKD/ESRD risk in females.

Because certain protective variants may accumulate during disease progression from GN/CKD to ESRD, we divided the patients into two categories: non-end stage GN/CKD and ESRD, and then analyzed their association with rs12696304 variants separately. For CKD cases, both G allele and GG genotype were significantly higher compared to those in controls (C vs G: OR = 1.555, 95% CI 1.215–1.990, P = 0.0001; CC + GC vs CC: OR = 1.634, 95% CI 1.201–2.234, P = 0.002; Table 3). Again, we only observed such differences between female controls and patients (C vs G: OR = 1.816, 95% CI 1.248–2.641,
Table 2  Genotyping results of rs12696304 and rs2736100 in controls and patients with GN/CKD/ESRD

|          | Controls (M + F) | Patients (M + F) | Odds ratio (95% CI) | P value | Controls (M only) | Patients (M only) | Odds ratio (95% CI) | P value | Controls (F only) | Patients (F only) | Odds ratio (95% CI) | P value |
|----------|------------------|------------------|---------------------|---------|-------------------|-------------------|---------------------|---------|-------------------|-------------------|---------------------|---------|
| rs12696304 (N) | 515 (100%) | 759 (100%) | 289 (100%) | 434 (100%) | 226 (100%) | 326 (100%) |       |
| CC | 56 (10.9) | 64 (8.4) | 32 (11.1) | 40 (9.2) | 24 (10.6) | 24 (7.4) |       |
| GC | 223 (43.3) | 275 (36.2) | 1.079 (0.723–1.609) | 0.709 | 119 (41.2) | 157 (36.3) | 1.055 (0.626–1.779) | 0.840 | 104 (46.0) | 118 (36.2) | 1.135 (0.608–2.118) | 0.692 |
| GG | 236 (45.8) | 420 (55.4) | 1.557 (1.052–2.306) | 0.026 | 138 (47.7) | 197 (45.5) | 1.079 (0.723–1.609) | 0.709 | 119 (41.2) | 157 (36.3) | 1.055 (0.626–1.779) | 0.840 |
| CC + GC | 279 (54.2) | 339 (44.6) | 1.008 (0.778–1.306) | 0.709 | 151 (52.3) | 237 (57.4) | 1.131 (0.973–1.767) | 0.089 | 128 (46.0) | 197 (45.5) | 1.135 (0.608–2.118) | 0.692 |
| GG | 236 (45.8) | 420 (55.4) | 1.465 (1.170–1.834) | 0.001 | 138 (47.7) | 237 (57.4) | 1.131 (0.973–1.767) | 0.089 | 128 (46.0) | 197 (45.5) | 1.135 (0.608–2.118) | 0.692 |
| C  | 335 (65.0) | 403 (26.5) | 1.008 (0.778–1.306) | 0.709 | 183 (61.7) | 237 (57.4) | 1.131 (0.973–1.767) | 0.089 | 152 (54.6) | 197 (45.5) | 1.135 (0.608–2.118) | 0.692 |
| G  | 695 (67.5) | 1115 (73.5) | 1.334 (1.22–1.586) | 0.001 | 395 (68.3) | 629 (72.6) | 1.230 (0.977–1.548) | 0.078 | 300 (66.4) | 486 (74.5) | 1.483 (1.140–1.929) | 0.003 |
| rs2736100 (N) | 515 (100%) | 757 (100%) | 289 (100%) | 426 (100%) | 226 (100%) | 331 (100%) |       |
| AA | 158 (30.7) | 222 (29.3) | 93 (32.2) | 138 (32.4) | 65 (28.8) | 84 (25.4) |       |
| AC | 257 (49.9) | 364 (48.1) | 1.008 (0.778–1.306) | 0.952 | 136 (47.1) | 201 (17.2) | 0.996 (0.708–1.401) | 0.982 | 121 (53.5) | 163 (49.2) | 1.042 (0.699–1.555) | 0.839 |
| CC | 100 (19.4) | 171 (22.6) | 1.217 (1.884–1.676) | 0.229 | 60 (20.7) | 87 (20.4) | 0.976 (0.641–1.489) | 0.914 | 40 (17.7) | 84 (25.4) | 1.625 (0.989–2.670) | 0.055 |
| A  | 573 (55.6) | 808 (53.4) | 1.008 (0.778–1.306) | 0.952 | 322 (55.7) | 477 (56.0) | 1.008 (0.778–1.306) | 0.952 | 251 (55.5) | 331 (50.0) | 1.008 (0.778–1.306) | 0.952 |
| C  | 475 (44.4) | 706 (46.6) | 1.008 (0.793–1.284) | 0.261 | 256 (43.3) | 375 (44.0) | 0.989 (0.799–1.223) | 0.918 | 201 (44.5) | 331 (50.0) | 1.249 (0.982–1.588) | 0.070 |

*GN* Glomerulonephritis, *CKD* chronic kidney disease, *ESRD* end-stage renal disease, *M* male, *F* female, *CI* confidence interval; italic *P* value: statistically significant
Table 3 The association of rs12696304 variants with primary GN/CKD risk

| rs12696304(N) | Controls (M + F) | Patients (M + F) | Odds ratio (95% CI) | P value | Controls (M only) | Patients (M only) | Odds ratio (95% CI) | P value | Controls (F only) | Patients (F only) | Odds ratio (95% CI) | P value |
|---------------|------------------|------------------|--------------------|---------|------------------|------------------|--------------------|---------|------------------|------------------|--------------------|---------|
| rs12696304    | Controls (M + F) | Patients (M + F) | Odds ratio (95% CI) | P value | Controls (M only) | Patients (M only) | Odds ratio (95% CI) | P value | Controls (F only) | Patients (F only) | Odds ratio (95% CI) | P value |
| rs12696304    | Controls (M + F) | Patients (M + F) | Odds ratio (95% CI) | P value | Controls (M only) | Patients (M only) | Odds ratio (95% CI) | P value | Controls (F only) | Patients (F only) | Odds ratio (95% CI) | P value |

GN Glomerulonephritis, CKD chronic kidney disease, M male, F female, CI confidence interval; italic P value: statistically significant
P = 0.002; CC + GC vs CC: OR = 1.959, 95% CI 1.233–3.114, P = 0.006; Table 3). There was no difference in the male groups (Table 3).

Similar distribution patterns of rs12696304 SNPs as seen above were also observed in the ESRD group: When a comparison including both males and females was made, the patient group exhibited significantly increased frequencies of G allele and GG genotype (C vs G: OR = 1.245, 95% CI 1.031–1.503, P = 0.022; CC + GC vs CC: OR = 1.392, 95% CI 1.089–1.778, P = 0.010; Table 4); whereas again a separate analysis showed that the difference was confined to the female groups (Table 4).

The association between the rs2376100 C allele or CC genotype and susceptibility to ESRD

The TERT rs2736100 genotyping was performed in these same controls and patients, and the obtained allele and genotype distribution is shown in Table 2. There was no significant difference in allele or genotype frequencies between controls and patients, or between males and females. However, the analysis of the ESRD subgroup revealed significantly increased frequencies of rs2736100 C allele and CC genotype in female patients compared to their matched healthy controls (A vs C: OR = 1.306, 95% CI 1.035–1.698, P = 0.046; AA vs CC: OR = 1.781, 95% CI 1.033–3.070, P = 0.037; Table 4).

LTL in healthy controls and patients

LTL was assessed in 327 controls and 592 patients. In both controls and patients, LTL was negatively correlated with age (P < 0.001) (Fig. 1a). LTL, as assessed using qPCR, was 1.187 ± 0.539 and 1.189 ± 0.593 (mean ± SD) for controls and patients, respectively, which did not differ significantly (P = 0.967) (Fig. 1b). Because females in general harbour longer LTL than men, and our results showed an association of telomerase gene variants with in female patients, we further compared LTL between controls and patients according to sex. A total of 159 male controls had LTL 1.160 ± 0.5359, while 363 male patients had LTL 1.193 ± 0.6013 (P = 0.967) (Fig. 1c). In females, a slightly shorter LTL was observed in patients (n = 229) compared to that in controls (n = 168) (1.182 ± 0.580 vs 1.213 ± 0.542, however, the difference did not reach a significant level (P = 0.590).

As TERC rs12696304 and TERT rs2736100 variants are both correlated with LTL [21, 22, 24–28, 33, 34], we compared LTL among different genotypes of controls and patients. LTL was 1.055 ± 0.456, 1.210 ± 0.570 and 1.204 ± 0.521 for control CC-, GC- and GG-carriers, respectively, and while 1.129 ± 0.525, 1.230 ± 0.628 and 1.167 ± 0.574 for patient CC-, GC- and GG-carriers, respectively (Fig. 1d). There were no differences among the three different genotypes of both controls and patients, or between controls and patients with the same genotype (Fig. 1e). The comparison of LTL among rs2736100 variants similarly showed the lack of any association between controls and patients irrespective of sex.

Discussion

Numerous studies have revealed an intimate association between the variants of the TERT or TERC gene and susceptibility to cancer, aging-associated disorders and many other pathological conditions [15, 21–28, 34, 35], however, their relationship with primary GN/CKD/ESRD has never been explored. In the present study, we investigated the influence of rs2736100 and rs12696304 variants on primary GN/CKD/ESRD risk, and the obtained results demonstrate significantly higher frequencies of the rs12696304 G allele and GG genotype in patients than in healthy controls, which indicate that the TERC rs12696304 G allele serves as a biomarker to GN/CKD/ESRD risk. We further observed that such susceptibility occurred only in females with the G allele/GG genotype. The rs2736100 variants are in general not associated GN/CKD risk, but the proportion of female ESRD C allele-carriers was significantly higher compared to their matched control counterparts, suggesting its role in CKD progression. Thus, the present findings provide evidence that the telomerase gene SNPs contribute to susceptibility to primary GN/CKD/ESRD.

An autoimmune etiology is strongly implicated in the pathogenesis of primary glomerular diseases/CKDs/ESRDs, while telomerase and telomeres have long been established to play an important role in regulating immunological activity [36, 37]. Activation of telomerase via induction of TERT and TERC expression occurs in activated lymphocytes for their proliferation and clonal expansion in response to infectious challenge [36, 37]. Shorter LTL was associated with increased susceptibility to experimentally induced acute upper respiratory infection and clinical illness in adults [38]. Mechanistically, shorter telomeres limit proliferative potentials of immune cells and compromise immune response to pathogens, thereby lowering host resistance to infection [36, 37]. In addition, telomerase insufficiency and shorter TL due to defective TERT and TERC expression were observed in naïve CD4 T cells from patients with rheumatoid arthritis, through which premature senescence of T cell subsets occurred and subsequent autoimmunity was triggered [39, 40]. Moreover, this scenario was also present in other autoimmune disorders [40]. TERT and TERC are two key components of the telomerase enzyme and it is thus conceivable that their genetic variants may affect telomerase activity. Likely, TERT and TERC variants modify risk of GN/CKD/ESRD by influencing the host immune activity.
| Patients (M + F) | Odds ratio (95% CI) | P value | Controls (M only) | Odds ratio (95% CI) | P value | Patients (F only) | Odds ratio (95% CI) | P value |
|-----------------|---------------------|---------|-------------------|---------------------|---------|-------------------|---------------------|---------|
| 516 (100%)      | 289 (100%)          | 300 (100%) | 226 (100%)        | 216 (100%)          |         |
| 51 (9.9%)       | 1.0 (ref)           | 32 (11.1) | 31 (10.3)         | 1.0 (ref)           |         |
| 186 (36.0)      | 0.916 (0.598–1.403) | 0.686   | 119 (41.2)        | 108 (36.0)          | 0.937 (0.536–1.637) | 0.819           | 104 (46.0)        | 78 (36.1)   | 0.900 (0.464–1.745) | 0.755 |
| 279 (54.1)      | 1.298 (0.855–1.970) | 0.219   | 138 (47.7)        | 161 (53.7)          | 1.204 (0.699–2.074) | 0.502           | 98 (43.4)         | 118 (54.6)  | 1.445 (0.753–2.771) | 0.266 |
| 237 (45.9)      | 1.0 (ref)           | 151 (52.3) | 139 (46.3)       | 1.0 (ref)           |         | 128 (56.6)        | 98 (45.4)          | 1.0 (ref) |
| 279 (54.1)      | 1.392 (1.089–1.778) | 0.010   | 138 (47.7)        | 161 (53.7)          | 1.267 (0.917–1.752) | 0.176           | 98 (43.4)         | 118 (54.6)  | 1.573 (1.080–2.289) | 0.023 |
| 288 (27.9)      | 1.0 (ref)           | 183 (31.7) | 170 (28.3)       | 1.0 (ref)           |         | 152 (33.6)        | 118 (27.3)         | 1.0 (ref) |
| 744 (72.1)      | 1.245 (1.031–1.503) | 0.022   | 395 (68.3)        | 430 (71.7)          | 1.172 (0.913–1.504) | 0.213           | 300 (66.4)        | 314 (72.7)  | 1.348 (1.011–1.798) | 0.042 |
| 520 (100%)      | 289 (100%)          | 297 (100%) | 226 (100%)        | 223 (100%)          |         |
| 156 (30.0)      | 1.0 (ref)           | 93 (32.2) | 104 (35.0)        | 1.0 (ref)           |         | 65 (28.8)         | 52 (23.3)          | 1.0 (ref) |
| 248 (47.7)      | 0.977 (0.737–1.295) | 0.873   | 136 (47.1)        | 134 (45.1)          | 0.881 (0.610–1.273) | 0.500           | 121 (53.5)        | 114 (51.1)  | 1.178 (0.754–1.839) | 0.472 |
| 116 (22.3)      | 1.175 (0.830–1.662) | 0.363   | 60 (20.7)         | 59 (19.9)           | 0.879 (0.558–1.387) | 0.580           | 40 (17.7)         | 57 (25.6)  | 1.781 (1.033–3.070) | 0.037 |
| 560 (33.8)      | 1.0 (ref)           | 322 (55.7) | 342 (57.6)       | 1.0 (ref)           |         | 251 (55.5)        | 218 (48.9)         | 1.0 (ref) |
| 480 (46.2)      | 1.075 (0.904–1.278) | 0.415   | 256 (44.3)        | 252 (42.4)          | 0.927 (0.736–1.168) | 0.519           | 201 (44.5)        | 228 (51.1)  | 1.306 (1.005–1.698) | 0.046 |

ESRD: End-stage renal disease, M: male, F: female, CI: confidence interval; italic P value: statistically significant
However, the LTL comparison between healthy controls and GN/CKD/ESRD patients did not reveal a significant difference, which indicates that telomere homeostasis is not substantially impaired. In addition, the rs12696304 G allele-carriers were previously shown to have significantly shorter LTL in both Chinese and western populations [22, 24–26], but we did not find such a scenario in either healthy controls or patients, and therefore the association between rs12696304 G allele and increased GN/CKD/ESRD risk is unlikely attributable to telomere length regulation. Telomere shortening is the canonical function of telomerase, whereas recent studies have demonstrated its multiple properties independently of telomere homeostasis [11, 41–48]. TERC or TERT has been shown to stimulate the activation of NK-κB pathway to promote inflammatory response independently of telomerase-mediated telomere extension [41, 48], while NK-κB is critical to drive CDK development and progression [49]. The rs12696304 G allele may be involved in a host auto-immune response targeting glomerular tissues via TERC-mediated activation of the NF-κB signalling pathway, which calls for further investigations.

It is intriguing that there exists an association between rs12696304 G allele or GG genotype and GN/CKD/ESRD risk only in females. Because estrogen and progesterone are known to activate the transcription of TERT and TERC genes [50–53], female sex hormones may play a putative part. As described above, impaired TERT or TERC expression in T cells are involved in the pathogenesis of rheumatoid arthritis. There may be a possibility that female hormones interact with the rs12696304 G allele, thereby contributing to dysregulation of TERC and subsequently leading to an auto-immune attack to glomerular tissues. Further studies are required to elucidate this issue.

Interestingly, we notice a significant difference in the rs12696304 variant distribution between Chinese Han and other ethnic populations. The results reported by us and other investigators showed that the CC genotype was restricted to 9 to 11% in the Chinese population [24], while it was present in more than 30% of Caucasians [22, 25, 26]. It has been well documented that the prevalence of primary GN/CKD/ESRD including IgA nephropathy is substantially higher in China than in Europe and North America, and the genotype difference in rs12696304 likely contributes to this difference in incidence patterns [2]. Similarly, we recently observed the different genotype distribution in the TERT rs2736100 between Swedish and Chinese populations [33]. A significantly higher fraction of rs2736100 C, a risk allele associated with myeloproliferative neoplasia (MPN), was seen in Swedish individuals, which is coupled with a higher incidence of MPN (than that in China) [33]. Collectively, different genotype distributions of telomerase SNPs between Eastern and Western countries may contribute to their different susceptibilities to a wide spectrum of diseases including glomerular diseases.

Our findings also showed that the rs2736100 C allele was associated with ESRDs, but not with non-end stage CKDs. It is likely that this allele contributes to CKD progression or ESRD risk. On the other hand, it may play a protective role in the disease evolution from CKD to ESRD, which thus leads to the selective accumulation of ESRD C allele-carriers.

**Conclusions**

The results presented here reveal an association between the rs12696304 G allele or GG genotype and susceptibility to primary glomerular diseases including CKD and ESRD in females. The G allele was shown to be correlated with shorter LTL in a number of studies, but we failed to see such difference in LTL between C and G allele-carriers in both controls and patients. Moreover, we further found that the TERT rs2736100 C allele or CC genotype frequency was higher in female ESRD patients but not in those with CKD, and it is currently unclear whether this is due to evolutional selection during disease progression. Premature telomere erosion has been reported in patients with CKD/ESRD, however, LTL differences were not observed between controls and patients here. Collectively, the TERC rs12696304 variant, and likely the TERT rs2736100 polymorphism, but not LTL per se, are associated with an increased risk of primary glomerular diseases. The present findings provide new insights into telomerase biology and glomerular disease etiology, and may be implicated in the precision prevention/intervention of CKD/ESRD.
Abbreviations
CKD: Chronic kidney disease; ESRD: End-stage renal disease; GN: Glomerulonephritis; LTL: Leukocyte telomere length; SNP: Single nucleotide polymorphism; TERC: Telomerase RNA component; TERT: Telomerase reverse transcriptase.

Acknowledgements
Not applicable.

Authors’ contributions
Research conception and study design: FK, WL, GL, MB and DX, Research and data analysis: QS, JL, GC, MD, ZQ, JL, and JZ. Manuscript preparation: FK, WL, GL, MB and DX. Clinical data collection: OS, WL and GL. Research sample preparation: QS, JL, GC, MD, ZQ, JL, and JZ. All authors have read the journal’s authorship agreement and agree with the statements. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved. All authors read and approved the final manuscript.

Funding
The study was supported by Grants from Shandong Provincial Natural Science Foundation, China (2016ZDJ507A09), the Swedish Cancer Society, Swedish Research Council, Cancer Society in Stockholm, Professor Nanna Svartzell Foundation and Karolinska Institutet. Open access funding provided by Karolinska Institute.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study was approved by the Ethics Review Committee of Shandong University Second Hospital and informed consent was obtained from all participants.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Central Research Laboratory, Shandong University Second Hospital, Jinan 250035, People’s Republic of China. 2 Laboratory for Molecular Diagnostics, Shandong University Second Hospital, Jinan 250035, People’s Republic of China. 3 Department of Nephrology, Shandong University of Traditional Chinese Medicine Affiliated Hospital, Jinan 250013, People’s Republic of China. 4 Nephrology Research Institute of Shandong University, Shandong University Second Hospital, Jinan 250035, People’s Republic of China. 5 Department of Medicine, Center for Molecular Medicine and Bioclinicum, Karolinska Institutet, Karolinska University Hospital Solna, SE-171 76 Stockholm, Sweden.

Received: 15 July 2019   Accepted: 17 April 2020
Published online: 04 May 2020

References
1. Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379(9811):165–80.
2. Liu ZH. Nephropathy in China. Nat Rev Nephrol. 2013;9(9):523–8.
3. Nugent RA, Fathima SF, Feigl AB, Chyung D. The burden of chronic kidney disease on developing nations: a 21st century challenge in global health. Nephron Clin Pract. 2011;118(3):c269–77.
4. Kuryk K, Novak J, Gharavi AG. Pathogenesis of immunoglobulin A nephropathy: recent insight from genetic studies. Ann Rev Med. 2013;64:339–56.
5. Zhang YM, Zhou XJ, Zhang H. What genetics tells us about the pathogenesis of IgA nephropathy: the role of immune factors and infection. Kidney Int Rep. 2017;2(3):318–31.
6. Zhu L, Zhang H. The genetics of IgA nephropathy: an overview from China. Kidney Dis (Basel). 2015;11(1):27–32.
7. Canadas-Garre M, Anderson K, McGoldrick J, Maxwell AP, McKnight AJ. Genomic approaches in the search for molecular biomarkers in chronic kidney disease. J Transl Med. 2018;16(1):292.
8. Liu D, Zhang J, Shi Y, Liu Z. Gene polymorphism and risk of idiopathic membranous nephropathy. Life Sci. 2019;229:124–31.
9. Yang F, Lai X, Deng L, Liu X, Li J, Zeng S, Zhang C, Hocher CF, Hocher B. Association of endothelin-1 gene polymorphisms with the clinical phenotype in primary nephrotic syndrome of children. Life Sci. 2014;118(2):446–50.
10. Calado RT, Young NS. Telomere diseases. N Engl J Med. 2009;361(24):2535–63.
11. Yuan X, Xu D. Telomerase reverse transcriptase (TERT) in action: cross-talking with epigenetics. Int J Mol Sci. 2019;20(13):3338.
12. Yuan X, Larsson C, Xu D. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players. Oncogene. 2019;38(34):6172–83.
13. Daniel M, Peek GW, Tellefsbøl TO. Regulation of the human catalytic subunit of telomerase (hTERT). Gene. 2012;498(2):135–46.
14. Noor-Abu-Jensen K, Rosen A, Raaschow P, Braund PS, Mollien J, Paulsson-Karlsson Y, Ballaks P, Lohi O, Ahmed A, Kittang AO, et al. Novel variants in Nordic patients referred for genetic testing of telomere-related disorders. Eur J Hum Genet. 2018;26(6):858–67.
15. Yuan X, Kronstrom M, Helenius ML, Cederholm T, Xu D, Sjogren P. Longitudinal changes in leukocyte telomere length and mortality in elderly Swedish men. Aging. 2018;10(10):3005–16.
16. Madzi M, Rezaie P, Covic A, Malyszko J, Rysz J, Bengtsson P, Banehuch AP. Telomere attrition, kidney function, and prevalent chronic kidney disease in the United States. Oncotarget. 2017;8(46):80175–81.
17. Ameh DI, Olpechi IG, Dandara C, Bengtsson P. Association between telomere length, chronic kidney disease, and renal traits: a systematic review. OMICS. 2017;21(3):143–55.
18. Li P, Tian C, Ge N, Wang H, Liu L, Lou F, Bjorkholm M, Xu D. Premature senescence of T cells in long-term survivors of renal transplantation. Biochem Biophys Res Commun. 2011;407(3):599–604.
19. Carrero JJ, Stenvinkel P, Fellstrom B, Qureshi AR, Lamb K, Heimburger O, Barany P, Radhakrishnan K, Lindholm B, Soveri 1, et al. Telomere attrition is associated with inflammation, low fetuin-A levels and high mortality in prevalent haemodialysis patients. J Intern Med. 2008;263(3):302–12.
20. Kato S, Shielis PG, McGuinness M, Lindholm B, Stenvinkel P, Nordfors L, Qureshi AR, Yuzawa Y, Matsuou S, Maruyama S. Telomere attrition and elongation after chronic dialysis initiation in patients with end-stage renal disease. Blood Purif. 2016;41(1–3):25–33.
21. Morellin S, Verdi D, Pooler KA, Landi MT, Egman KM, Baird DM, Precott J, De Vivo I, Nitti D. Telomerase reverse transcriptase locus polymorphisms and cancer risk: a field synopsis and meta-analysis. J Nat Cancer Inst. 2012;104(1):840–54.
22. Soerensen M, Thinggaard M, Nygaard M, Dato L, Himmelborg J, Andersen-Ranberg K, Stevnsner T, Bohr VA, Kimura M, et al. Genetic variation in TERT and TERC and human leukocyte telomere length and longevity: a cross-sectional and longitudinal analysis. Aging Cell. 2012;11(2):223–7.
23. Turnbull C, Rapley EA, Seal S, Pernet D, Renwick A, Hughes D, Ricketts M, Linger R, Nsengimana J, Deloukas P, et al. Variants near DMRT1, TERT and TERC are associated with leukocyte telomere length in the Chinese Han population. Eur J Hum Genet. 2010;18(7):604–7.
24. Shen Q, Zhang Z, Wang H, Liu L, Lou F, Bjorkholm M, Xu D. Premature senescence of T cells in long-term survivors of renal transplantation. Biochem Biophys Res Commun. 2011;407(3):599–604.
25. Carrero JJ, Stenvinkel P, Fellstrom B, Qureshi AR, Lamb K, Heimburger O, Barany P, Radhakrishnan K, Lindholm B, Soveri 1, et al. Telomere attrition is associated with inflammation, low fetuin-A levels and high mortality in prevalent haemodialysis patients. J Intern Med. 2008;263(3):302–12.
26. Mocellin S, Verdi D, Pooler KA, Landi MT, Egman KM, Baird DM, Precott J, De Vivo I, Nitti D. Telomerase reverse transcriptase locus polymorphisms and cancer risk: a field synopsis and meta-analysis. J Nat Cancer Inst. 2012;104(1):840–54.
27. Soerensen M, Thinggaard M, Nygaard M, Dato L, Himmelborg J, Andersen-Ranberg K, Stevnsner T, Bohr VA, Kimura M, et al. Genetic variation in TERT and TERC and human leukocyte telomere length and longevity: a cross-sectional and longitudinal analysis. Aging Cell. 2012;11(2):223–7.
28. Turnbull C, Rapley EA, Seal S, Pernet D, Renwick A, Hughes D, Ricketts M, Linger R, Nsengimana J, Deloukas P, et al. Variants near DMRT1, TERT and TERC are associated with leukocyte telomere length in the Chinese Han population. Eur J Hum Genet. 2010;18(7):604–7.
27. Dluouha D, Pitka J, Mesanyova J, Mirazkova J, Fellnerova A, Stanek V, Lanska V, Hubacek J. Genetic variants within telomere-associated genes, leukocyte telomere length and the risk of acute coronary syndrome in Czech women. Clin Chim Acta. 2016;454:2–5.
28. Mauabarret CG, Salpea KD, Romanoski CE, Folkers L, Cooper JA, Stephanoiu C, Li KW, Palmen J, Hamsten A, Neil A, et al. Association of TERC and OBFC1 haplotypes with mean leukocyte telomere length and risk for coronary heart disease. PLoS ONE. 2013;8(12):e83122.
29. Yuan X, Dai M, Xu D. Telomere-related markers for cancer. Curr Top Med Chem. 2020;20(6):410–32.
30. Yuan X, Cheng G, Yu J, Zheng S, Sun C, Sun Q, Li K, Lin Z, Liu T, Li P, et al. The TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinoma. Oncotarget. 2017;8(14):23120–9.
31. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res. 2002;30(10):e47.
32. Cheng G, Yuan X, Wang F, Sun Q, Xin Q, Li K, Sun C, Lin Z, Yuan Y, Xu Y, et al. Association between the telomerase rs2736098_TT genotype and a lower risk of chronic hepatitis B and cirrhosis in Chinese males. Clin Transl Gastroenterol. 2017;8(3):e79.
33. Dahlstrom J, Liu T, Yuan X, Saft L, Ghaderi M, Wei YB, Lavebratt C, Li P, Zheng C, Bjorkholm M, et al. TERT rs2736100 genotypes are associated with differential risk of myeloproliferative neoplasms in Swedish and Chinese male patient populations. Ann Hematol. 2016;95(11):1825–32.
34. McKay JD, Hong RJ, Marion M, Boffetta P, Chabrier A, Byrnes G, Zaridze D, Mukeria A, Szeszenia-Dabrowska N, Lissowska J, et al. Lung cancer susceptibility locus at 5p15.33. Nat Genet. 2008;40(12):1404–6.
35. Melin BS, Nordfjall K, Andersson U, Roos G. hTERT cancer risk genotypes are associated with telomere length. Genet Epidemiol. 2012;36(4):366–72.
36. Weng NP. Telomeres and immune competency. Curr Opin Immunol. 2012;24(4):470–5.
37. Ge Z, Liu C, Bjorkholm M, Gruber A, Xu D. Mitogen-activated protein kinase cascade-mediated histone H3 phosphorylation is critical for telomerase reverse transcriptase expression/telomerase activation induced by proliferation. Mol Cell Biol. 2006;26(1):230–7.
38. Cohen S, Janicki-Deverts D, Turner RB, Casselbrant ML, Li-Korotky HS, Epel ES, Doyle WJ. Association between telomere length and experimentally induced upper respiratory viral infection in healthy adults. JAMA. 2013;309(7):705.
39. Fuji H, Shao L, Colmegna I, Goronyz JJ, Weyand CM. Telomerase insufficiency in rheumatoid arthritis. Proc Nat Acad Sci USA. 2009;106(11):4560–5.
40. Fessler J, Racht A, Husic R, Ficjan A, Dufneter C, Schwinger W, Dejaco C, Schirmer M. Premature senescence of T-cell subsets in axial spondyloarthritis. Ann Rheum Dis. 2016;75(4):748–54.
41. Ding D, Xi P, Zhou J, Wang M, Cong YS. Human telomerase reverse transcriptase regulates MMP expression independently of telomerase activity via NF-kappaB-dependent transcription. Faseb J. 2014;27(11):4375–83.
42. Liu T, Liang X, Li B, Bjorkholm M, Jia J, Xu D. Telomerase reverse transcriptase inhibition stimulates cyclooxygenase 2 expression in cancer cells and synergizes with celecoxib to exert anti-cancer effects. Br J Cancer. 2013;108(11):2272–80.
43. Liu Z, Li Q, Li K, Chen L, Li W, Hou M, Liu T, Yang J, Lindvall C, Bjorkholm M, et al. Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells. Oncogene. 2013;32(36):4203–13.
44. Singhapal C, Pal D, Czepiowski R, Ronika M, Nelson G, Saretzki G. Mitochondrial telomerase protects cancer cells from nuclear DNA damage and apoptosis. PLoS ONE. 2013;8(1):e52989.
45. Luiten RM, Pene J, Yssel H, Spits H. Ectopic hTERT expression extends the life span of human CD4+ helper and regulatory T-cell clones and confers resistance to oxidative stress-induced apoptosis. Blood. 2003;101(11):4512–9.
46. Li X, Li B, Ma X, Kong F, Zheng C, Bjorkholm M, Jia J, Xu D. Bortezomib-mediated down-regulation of telomerase and disruption of telomere homeostasis contributes to apoptosis of malignant cells. Oncotarget. 2015;6(635):38079–92.
47. Saretzki G. Extra-telomeric functions of human telomerase: cancer, mitochondria and oxidative stress. Curr Pharmaceut Des. 2015;20(4):6386–403.
48. Liu H, Yang Y, Ge Y, Liu J, Zhao Y. TERC promotes cellular inflammatory response independent of telomerase. Nucleic Acids Res. 2019;47(15):8084–95.
49. Wang M, Xu H, Chong Lee Shin OL, Li L, Gao H, Zhao Z, Zhu F, Zhu H, Liang W, Qian K, et al. Compound alpha-keto acid tablet supplementation alleviates chronic kidney disease progression via inhibition of the NF-kB and MAPK pathways. J Transl Med. 2019;17(1):122.
50. Misiti S, Nanni S, Fontemaggi G, Cong YS, Wen J, Hiret HW, Piaggio G, Scachi A, Pontecorvi A, Bacchetti S, et al. Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelial cells. Mol Cell Biol. 2000;20(11):3764–71.
51. Wang Z, Kyo S, Takakura M, Tanaka M, Yatabe N, Maida Y, Fujimura M, Hayakawa J, Ohyama K, Koike K, et al. Progerestone regulates human telomerase reverse transcriptase gene expression via activation of mitogen-activated protein kinase signaling pathway. Cancer Res. 2020;80(619):5376–81.
52. Vidal JD, Register TC, Gupta M, Cline JM. Estrogen replacement therapy induces telomerase RNA expression in the macaque endometrium. Fertil Steril. 2002;77(3):601–8.
53. Kyö S, Takakura M, Kanaya T, Zhuo W, Fujimoto K, Nishio Y, Ohnishi A, Inoue M. Estrogen activates telomerase. Cancer Res. 1999;59(23):5917–21.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.